NEW

Getinge, Cook Medical Reach iCast Distribution Agreement

Getinge and Cook Medical have announced an exclusive sales and distribution agreement for the iCast covered stent system.

Endorail Earns FDA 510(k) clearance: Next-generation magnetic balloon technology optimizes colonoscopy procedural outcomes

Endostart, a pioneering medical device company specializing in gastrointestinal endoscopy solutions, HAS announces a major breakthrough with the FDA 510(k) clearance of its flagship product, Endorail. This achievement represents a significant step forward in advancing...

Survey: Nurse Shortage a Leading Threat to Industry

In honor of Certified Nurses Day, health tech company Carta Healthcare®, whose mission is to harness the value of clinical data, today released the results of a survey about the pain points that health care professionals are currently experiencing. The survey also...

Modular Lab Furniture Systems Meet Needs

UniLine Furniture offerings from HEMCO Corp. include base cabinets, wall cabinets, countertops, sinks, fixtures, base tables, mobile work stations, specialty storage cabinets and peg boards.

Longest Study of Magnetic Sphincter Augmentation Shows Durable Efficacy of Linx® Reflux Management System

LINX Eliminated Daily Dependance on Acid-Reflux Medications in 79% of GERD Patients 

CINCINNATI – Nov. 10, 2020 – Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, announced today its LINX® Reflux Management System was shown to provide effective long-term control of gastroesophageal reflux disease (GERD) and eliminated the need for daily reflux medications in 79% of patients in the longest-term study ever published on magnetic sphincter augmentation (MSA).1 The study, which followed patients over a 6- to 12-year period, recently appeared in the journal Nature Scientific Reports.

The LINX Reflux Management System is a flexible ring of small magnets placed around the lower part of the esophagus, the body’s natural barrier to reflux, during a minimally invasive procedure. The magnetic ring expands when a person ingests food and then contracts to prevent stomach contents, including gastric acid, from backing up into the esophagus and causing GERD, a condition that affects about 20% of people in the United States.3

In the single-center (IRCCS Policlinico San Donato in Italy) retrospective study of 335 patients who had an MSA procedure with LINX between 2007 and 2020, 124 patients who had been implanted for at least 6 years and up to 12 (median 9 years) were followed. Nearly 90% of LINX patients experienced long-term favorable outcomes defined as a greater than 50% improvement in their GERD-health related quality of life (GERD-HRQL) score and the discontinued use of proton pump inhibitors (PPIs), the current standard of care in medical therapy.4 There were no device erosions or migrations and only three instances (2.4%) of device removal due to either continued reflux symptoms, dysphagia or the need for an MRI in this long-term group.2 Patient satisfaction was 93.8% after 10 years.2

“Our new study corroborates the findings of previous studies but over a longer period of time, which is important for an implanted device,” said study co-author Luigi Bonavina***, MD, Professor of Surgery at University of Milan School of Medicine and Chief of the Department of Surgery at IRCCS Policlinico San Donato. “The efficacy of the LINX System remained strong and the risk of complications did not increase many years after implantation. Based on these results and the high levels of patient satisfaction, MSA may represent a true paradigm shift that has the potential to fill the current therapy gap in GERD.”

This latest study builds on more than 50 peer-reviewed articles,5 including a randomized clinical trial, that show procedures with the LINX System are more effective than twice-daily PPIs in normalizing reflux6 and more effective in reducing disease-related payer cost 12 months post-surgery than laparoscopic Nissen fundoplication, a more invasive anti-reflux surgery.7

Several GI and surgical societies, including the American Society of General Surgeons (ASGS), Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the American College of Gastroenterology (ACG) and the American Foregut Society (AFS), have issued consensus statements in favor of LINX procedures for appropriate GERD patients.

“Despite extensive clinical evidence, including this long-term study, and support from leading societies and academic centers, treatment with the LINX System remains out of reach for many patients due to inconsistent insurance coverage throughout the U.S.,” said Tom O’Brien, Worldwide Endomechanical President, Ethicon. “We are committed to providing the clinical and economic evidence that insurance carriers demand so patients with severe GERD can finally have access to the long-term relief they need and the potential for an improved quality of life wherever they happen to live.”

About the LINX Reflux Management System
The LINX Reflux Management System is indicated for those patients diagnosed with GERD as defined by abnormal pH testing, and who are seeking an alternative to continuous acid suppression therapy. LINX requires a surgical procedure and is associated with potential risks, contraindications and lifestyle modifications. For more information about LINX, or to find a physician, visit www.linxforlife.com. LINX is manufactured by Torax® Medical, Inc., 4188 Lexington Avenue North, Shoreview, Minnesota 55126, USA.

About Ethicon 
From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world’s most pressing healthcare issues and improve and save more lives. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treat serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com, and follow us on Twitter and LinkedIn.

About the Johnson & Johnson Medical Devices Companies
The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, interventional and specialty solutions with an offering directed at delivering clinical and economic value to health care systems worldwide.

*Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates.
** The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
*** Luigi Bonavina, MD is a paid consultant for Ethicon.

  1. Complete cessation of daily dose PPIs observed in 79% of patients at 9-year median follow up (n=124). Ferrari D, Asti E, Lazzari V, et al. Six to 12-year outcomes of magnetic sphincter augmentation for gastroesophageal reflux disease. Sci Rep. 2020. 10(13753).
  2. Ferrari D, Asti E, Lazzari V, et al. Six to 12-year outcomes of magnetic sphincter augmentation for gastroesophageal reflux disease. Sci Rep. 2020;10(1):13753. doi:10.1038/s41598-020-70742-3.
  3. El-Serag HB, Sweet S, Winchester C, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014. 63(6): 871-80. Poisson regression model of 16 studies yielded a sample size-weighted mean of 19.8% for the prevalence of GERD in the US.
  4. Based upon a 6-12 years follow up study of 124 patients. Favorable outcomes were defined as ≥ 50% improvement in GERD-HRQL total score and PPI discontinuation. Ferrari D, Asti E, Lazzari V, et al. Six to 12-year outcomes of magnetic sphincter augmentation for gastroesophageal reflux disease. Sci Rep. 2020. 10(13753).
  5. https://www.americanforegutsociety.org/wp-content/uploads/2019/10/AFS-LINX-Final.pdf
  6. Based on a RCT comparing patients on twice-daily PPI (BID PPI) to  patients treated with laparoscopic MSA who all underwent impedance-pH testing. 91% of MSA patients vs. 58% of BID PPI patients had a normal number of reflux episodes at 6 months (p<0.001).  Bell R, Lipham J, Louie B, et al. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: A randomized controlled trial. 2018.  Gastrointestinal Endoscopy.
  7. Ayazi S, Zaidi AH, Zheng P, et al. Comparison of surgical payer costs and implication on the healthcare expenses between laparoscopic magnetic sphincter augmentation (MSA) and laparoscopic

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X